Rodríguez-Carmona Ana, Fontán Miguel Pérez
Division of Nephrology, Hospital Juan Canalejo, A Coruña, Spain.
Perit Dial Int. 2002 Nov-Dec;22(6):705-13.
To compare sodium removal in continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) patients, and to identify the main factors that modify Na removal in clinical practice in these patients.
Study in three steps. Cross-sectional observational (Study A), and longitudinal interventional (Studies B and C).
First (Study A) we carried out a cross-sectional survey of Na removal in 63 patients on CAPD and 78 patients on APD. Second (Study B), we studied Na removal in 32 patients before and after changing from CAPD to APD therapy. Finally (Study C), we analyzed the impact on Na removal of introducing icodextrin for the long dwell in 16 patients undergoing CAPD or APD.
In Study A, total Na removal averaged 210 mmol/day for CAPD patients and 91 mmol/day for APD patients (p < 0.001); Na removal was < 100 mmol/day in 7.1% of CAPD patients and 56.4% of APD patients. Multivariate analysis identified ultrafiltration [B = 125 mmol/day, 95% confidence interval (CI) 110,140], CAPD therapy (B = 60 mmol/day, 95%CI 37, 83), and residual diuresis (B = 51 mmol/L, 95%CI 34, 69) as independent predictors of Na removal (adjusted r2 = 0.76). For APD patients, longer nocturnal dwell times and performing a supplementary diurnal exchange were also independently associated with higher Na removal rates. In Study B, Na removal decreased from 192 to 92 mmol/day (median) after the change to APD (p = 0.02). In Study C, peritoneal Na removal increased from 98 to 148 mmol/day (median) (p = 0.04) after introducing icodextrin.
Standard APD schedules are frequently associated with poor Na removal rates. For any degree of ultrafiltration, Na removal is better in CAPD than in APD. Icodextrin, supplementary diurnal exchanges, and longer nocturnal dwell times improve Na removal in APD. Sodium removal can be estimated from ultrafiltration in patients on CAPD, but must be specifically monitored in patients on APD.
比较持续性非卧床腹膜透析(CAPD)患者和自动化腹膜透析(APD)患者的钠清除情况,并确定在这些患者的临床实践中影响钠清除的主要因素。
分三个步骤进行研究。横断面观察性研究(研究A)以及纵向干预性研究(研究B和研究C)。
首先(研究A),我们对63例CAPD患者和78例APD患者的钠清除情况进行了横断面调查。其次(研究B),我们研究了32例从CAPD转换为APD治疗的患者在转换前后的钠清除情况。最后(研究C),我们分析了16例接受CAPD或APD治疗的患者使用艾考糊精进行长时间留腹对钠清除的影响。
在研究A中,CAPD患者的总钠清除平均为210 mmol/天,APD患者为91 mmol/天(p<0.001);7.1%的CAPD患者和56.4%的APD患者钠清除<100 mmol/天。多变量分析确定超滤量[B=125 mmol/天,95%置信区间(CI)110,140]、CAPD治疗(B=60 mmol/天,95%CI 37,83)和残余尿量(B=51 mmol/L,95%CI 34,69)为钠清除的独立预测因素(调整后r2=0.76)。对于APD患者,夜间留腹时间更长以及进行日间补充换液也与更高的钠清除率独立相关。在研究B中,转换为APD后钠清除量从192 mmol/天降至92 mmol/天(中位数)(p=0.02)。在研究C中,引入艾考糊精后腹膜钠清除量从98 mmol/天增加至148 mmol/天(中位数)(p=0.04)。
标准的APD方案常常与较差的钠清除率相关。对于任何程度的超滤,CAPD患者的钠清除情况优于APD患者。艾考糊精、日间补充换液以及更长的夜间留腹时间可改善APD患者的钠清除。CAPD患者的钠清除可通过超滤量进行估算,但APD患者必须进行专门监测。